Details for Patent: 4,837,378
Summary for Patent: 4,837,378
| Title: | Topical metronidazole formulations and therapeutic uses thereof | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Topical aqueous single-phase compositions containing metronidazole are disclosed. The compositions have improved specific activity and are substantially non-comedogenic, non-irritating and non-skin-drying. These aqueous topical compositions are particularly useful for treating rosacea and other acneform dermatological conditions, and certain forms of dermatitis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Robert J. Borgman | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Galderma SA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US07/144,252 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 4,837,378: Metronidazole Gel Claims, Scope, Expiration, and Patent LandscapeUS Patent 4,837,378 covers an aqueous topical metronidazole gel using a high-molecular-weight polyacrylic acid polymer. Its core protection requires metronidazole as the sole active ingredient, an aqueous vehicle, and a water-dispersible polyacrylic acid polymer with a molecular weight of approximately 1.25 million to 4 million daltons. The patent issued June 6, 1989, and its 17-year term from grant expired June 6, 2006, absent a term adjustment or extension that would alter the published term. It is no longer an enforceable barrier to generic metronidazole gel products. The patent is historically important because its formulation claims correspond closely to the type of 0.75% metronidazole carbomer gel commercialized for rosacea and related dermatological disorders. Current competition is governed primarily by FDA approval status, product-specific formulation development, manufacturing know-how, and any later patents, not by US Patent 4,837,378. What does US Patent 4,837,378 cover?The patent covers two related categories:
The independent composition claim, claim 1, requires every element below:
The claim is narrower than a general claim to topical metronidazole. It does not cover every cream, lotion, ointment, foam, solution, suspension, or gel containing metronidazole. A competing product would need to be assessed against the full combination of limitations. How broad is the composition claim?Claim 1 has moderate technical breadth but narrow legal structure. It does not require:
Those ingredients and parameters appear in dependent claims or the specification. A product may fall within claim 1 without falling within claims 2 through 14. The claim uses functional and structural language together. “Hydrophilic and water-dispersible polymer having free carboxylic groups” describes the polymer’s properties, while “polyacrylic acid polymer” and the molecular-weight range provide the principal structural limitations. Commercial carbomers and related crosslinked polyacrylic acid materials would require product-specific analysis because nomenclature, molecular-weight measurement, crosslinking, neutralization, and supplier specifications can affect claim mapping. What concentrations are protected by the dependent claims?Claims 2 through 7 narrow the active and polymer concentrations.
A formulation containing 0.75% metronidazole and approximately 0.6% qualifying polyacrylic acid polymer would be positioned within the central dependent-claim profile. The use of “about” introduces ordinary claim-construction questions concerning measurement precision and commercial formulation tolerances. It does not eliminate the requirement that the formulation be reasonably within the stated range. What excipients are protected by US 4,837,378?Claims 8 through 14 add specific excipient limitations. Propylene glycolClaims 8 through 10 cover a penetration enhancer, with propylene glycol specified at:
The claims do not require propylene glycol in the independent composition claim. A product without propylene glycol may still be evaluated under claim 1, but it would not meet claims 8 through 10 solely on that basis. PreservativesClaims 11 through 13 cover preservatives and parabens. Claim 13 specifies:
These limitations are formulation-specific. A product using phenoxyethanol, benzyl alcohol, potassium sorbate, or another preservative would not satisfy the paraben-specific claim solely because it contains a preservative. EDTAClaim 14 covers EDTA at approximately 0.01% to 0.1% by weight. The claim does not specify a particular EDTA salt in the supplied language. The identity of the salt, formulation pH, and equivalence of the measured ingredient would be relevant to a product comparison. What methods of treatment are protected?Claim 15 covers topical treatment of a human with one of four skin disorders:
The method requires applying a therapeutically effective amount of the same core aqueous metronidazole gel defined in claim 1. Claims 16 and 17 narrow the method to:
The method claims are not generic claims to treating any disease with metronidazole. They require the claimed gel composition and one of the specified disorders. They also require treatment of a human and topical application to the afflicted skin region. Does the patent cover MetroGel 0.75%?The claimed formulation profile is consistent with the technical architecture of 0.75% metronidazole aqueous gels used for rosacea. FDA labeling for MetroGel 0.75% identifies metronidazole as the active ingredient and describes a topical gel product with conventional dermatological excipients, including a carbomer-type gelling system in product formulations and labeling history. The exact commercial formula must be compared with the patent claims and the applicable product records rather than inferred solely from the brand name or strength.[2] A 0.75% metronidazole product could implicate claim 4 if it also contains a qualifying polyacrylic acid polymer within the claimed molecular-weight range. It would not necessarily satisfy the narrower claims requiring approximately 0.6% polymer, 3% propylene glycol, the specified paraben combination, or EDTA. When did US Patent 4,837,378 expire?US Patent 4,837,378 issued June 6, 1989. For a pre-June 8, 1995 US patent, the operative term generally was 17 years from issue under the applicable patent-term regime. On that basis, the ordinary expiration date was June 6, 2006.[1]
The patent therefore cannot support a new US infringement action against a current generic manufacturer. Its expired claims remain relevant for historical freedom-to-operate analysis, prior-art review, prosecution history, and interpretation of later patents, but not as an active exclusionary right. What is the FDA Orange Book status of the patent?The Orange Book identifies patents submitted by NDA sponsors for approved drug products and records patent expiration and regulatory exclusivity information. An expired patent may remain visible historically in Orange Book records even though it no longer blocks approval or marketing.[3] For metronidazole gel products, the relevant FDA regulatory pathway is the abbreviated new drug application pathway for generic products, not the biosimilar pathway. Metronidazole is a small-molecule drug. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for the relevant topical product. It does not file a biosimilar application under section 351(k) of the Public Health Service Act. The historical importance of US 4,837,378 is greater than its current Orange Book value. Its expiration removed the patent-based barrier associated with the original gel formulation. Any later-listed patents would have to be analyzed separately by NDA, product, claims, and expiration date. Were there Paragraph IV challenges to this patent?A Paragraph IV certification is an ANDA applicant’s assertion that a listed patent is invalid, unenforceable, or will not be infringed. Because US 4,837,378 expired in 2006, a current ANDA applicant would not ordinarily need to mount a live Paragraph IV challenge to this patent. The practical issue became expiration and launch timing rather than continuing litigation over an enforceable right. The existence of an ANDA certification, notice letter, or litigation involving a metronidazole gel product should not be treated as proof that the dispute concerned US 4,837,378. Topical metronidazole products have also been associated with later patents involving formulation, delivery, or other product characteristics. Those patents require separate identification in the applicable Orange Book and court records. What is the broader patent landscape for topical metronidazole?The landscape divides into five technical groups. Core metronidazole gel patentsUS 4,837,378 is the principal historical patent identified by the supplied claims. It covers the combination of metronidazole, aqueous solvent, and high-molecular-weight polyacrylic acid gel polymer. Its claims are now expired. Later formulation patentsLater patents may address:
A later formulation patent can remain relevant even when the original active-ingredient formulation patent has expired. The key question is whether the later patent claims a commercially necessary feature or merely an optional formulation design. Method-of-use patentsLater method claims may target:
Such claims may create labeling or induced-infringement issues only if the product labeling, promotional activity, and claim language align. The expired method claims in US 4,837,378 do not create that risk today. Manufacturing and process patentsPotential manufacturing barriers include:
Process know-how can affect product quality and cost even when no enforceable patent remains. Trade secrets and regulatory CMC information may therefore matter more than the expired composition claims. Product-specific regulatory exclusivityFDA exclusivity is separate from patent protection. New-drug exclusivity periods, pediatric exclusivity, and other statutory protections can delay approval or affect labeling even when a patent has expired. For an old metronidazole gel product, the commercially important regulatory barriers are generally historical. The current market is primarily controlled by approved product status, manufacturing capacity, state substitution rules, and commercial contracting.[3] How strong is the patent estate for metronidazole gel?The estate associated with US 4,837,378 has no current exclusionary strength because the patent expired. Its historical claim strength was concentrated in a specific formulation architecture rather than in metronidazole itself.
The patent would have been more difficult to avoid for a product using the same aqueous carbomer-type gel platform and the claimed polymer molecular-weight range. It would have been easier to design around with a different dosage form, a different polymer outside the claimed range, or a combination product that did not contain metronidazole as the sole active ingredient, subject to the full claim language and applicable doctrine of equivalents. Which companies compete with metronidazole gel?Competition has historically included the branded MetroGel product and generic metronidazole topical gels approved through ANDAs. Galderma has been associated with MetroGel and related dermatology products, while generic manufacturers have entered after the relevant patent and exclusivity barriers expired. Product ownership, marketing authorization, and distribution arrangements can change over time and should be tied to the current FDA product record. The main competitive variables are:
There is no biosimilar competitive segment for metronidazole gel. Biosimilar analysis applies to biological products, not this small-molecule topical drug. What generic launch scenarios existed after expiration?After June 6, 2006, a generic entrant could pursue several routes:
The principal launch risks were regulatory equivalence, topical bioequivalence, product quality, manufacturing scale-up, supply continuity, and possible later patents. US 4,837,378 itself did not prevent these launches after expiration. What geographic coverage does the patent have?US 4,837,378 provides rights only in the United States. It does not establish protection in Canada, Europe, Japan, or other markets. Foreign counterparts, national-phase applications, and separate continuation filings must be reviewed independently. The US patent’s expiration also does not establish the expiration date of any foreign family member. Foreign rights can differ because of:
A global freedom-to-operate conclusion cannot be based on the US patent alone. Key Takeaways
FAQs About US Patent 4,837,378Does US 4,837,378 claim metronidazole itself?No. The claims cover a specific topical composition and treatment method. They do not claim the metronidazole molecule as a compound. Does a 0.75% metronidazole cream infringe this patent?Not necessarily. Claim 1 requires an aqueous gel and a qualifying polyacrylic acid polymer. A cream lacking those elements would not meet the literal requirements of the independent claim. Does using a different carbomer avoid the patent?Not automatically. The analysis depends on whether the alternative polymer is a polyacrylic acid polymer with free carboxylic groups and a molecular weight within the claimed range. Can a company launch a generic metronidazole gel based only on this patent’s expiration?No. Patent expiration removes this patent barrier but does not eliminate FDA approval, quality, manufacturing, labeling, regulatory, or later-patent requirements. Is a rosacea indication still protected by this patent?No. The rosacea method claims expired with the patent. A later patent could create separate rights, but US 4,837,378 itself no longer provides enforceable protection. References
More… ↓ |
Drugs Protected by US Patent 4,837,378
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 4,837,378
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 103176 | ⤷ Start Trial | |||
| Austria | 103813 | ⤷ Start Trial | |||
| Australia | 3043289 | ⤷ Start Trial | |||
| Australia | 5829490 | ⤷ Start Trial | |||
| Australia | 621589 | ⤷ Start Trial | |||
| Brazil | 9006793 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
